Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

被引：113

作者：

Konstantinidou, Markella ^{[1
]}

Zarganes-Tzitzikas, Tryfon ^{[1
]}

Magiera-Mularz, Katarzyna ^{[2
]}

Holak, Tad A. ^{[2
,3
]}

Domling, Alexander ^{[1
]}

机构：

[1] Univ Groningen, Dept Drug Design, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands

[2] Jagiellonian Univ, Fac Chem, Ingardena 3, PL-30060 Krakow, Poland

[3] Max Planck Inst Biochem, Klopferspitz 18a, D-82152 Martinsried, Germany

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2018年 / 57卷 / 18期

基金：

新加坡国家研究基金会;

关键词：

antitumor agents; protein-protein interactions; PD-1; PD-L1; protein structures; PROGRAMMED DEATH-1; STRUCTURAL BASIS; CANCER-IMMUNOTHERAPY; CRYSTAL-STRUCTURE; HUMAN PD-1; CELL; INHIBITORS; BLOCKADE; LIGANDS; COMPLEX;

D O I：

10.1002/anie.201710407

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.

引用

页码：4840 / 4848

页数：9

共 50 条

[1] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, Durre
Zaheer, Samreen
Sureka, Niti
Trisal, Monal
Chaurasia, Jai Kumar
Zaheer, Sufian
PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
[2] Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
Sharma, Padmanee
CANCER RESEARCH, 2018, 78 (13)
[3] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
Magiera-Mularz, Katarzyna
Kuska, Katarzyna
Skalniak, Lukasz
Grudnik, Przemyslaw
Musielak, Bogdan
Plewka, Jacek
Kocik, Justyna
Stec, Malgorzata
Weglarczyk, Kazimierz
Sala, Dominik
Wladyka, Benedykt
Siedlar, Maciej
Holak, Tad A.
Dubin, Grzegorz
ADVANCED THERAPEUTICS, 2021, 4 (02)
[4] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Magiera-Mularz, Katarzyna
Skalniak, Lukasz
Zak, Krzysztof M.
Musielak, Bogdan
Rudzinska-Szostak, Ewa
Berlicki, Lukasz
Kocik, Justyna
Grudnik, Przemyslaw
Sala, Dominik
Zarganes-Tzitzikas, Tryfon
Shaabani, Shabnam
Doemling, Alexander
Dubin, Grzegorz
Holak, Tad A.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
[5] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
Hashimoto, Kazuhiko
Nishimura, Shunji
Akagi, Masao
DIAGNOSTICS, 2020, 10 (08)
[6] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
Duruisseaux, Michael
Rouquette, Isabelle
Adam, Julien
Cortot, Alexis
Cazes, Aurelie
Gibault, Laure
Damotte, Diane
Lantuejoul, Sylvie
ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
[7] PD-1 and PD-L1 antibodies for melanoma
Tsai, Katy K.
Zarzoso, Ines
Daud, Adil I.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116
[8] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
Dermani, Fatemeh K.
Samadi, Pouria
Rahmani, Golebagh
Kohlan, Alisa K.
Najafi, Rezvan
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325
[9] Immunohistochemistry of Immune Checkpoint Markers PD-1 and PD-L1 in Prostate Cancer
Sharma, Meenal
Yang, Qi
Mcmahon, Loralee
Miyamoto, Hiroshi
MODERN PATHOLOGY, 2019, 32
[10] The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
Wang, Qingshui
Lin, Wei
Tang, Xiaoqiong
Li, Suhuan
Guo, Libin
Lin, Yao
Kwok, Hang Fai
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)

← 1 2 3 4 5 →